Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) on Thursday revealed clinical results from its MRT-6160 Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) study.

The study objectives were to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics, including VAV1 degradation and its impact on T and B cell function following ex vivo stimulation.

Results demonstrated sustained, dose-dependent VAV1 degradation of greater than 90% in peripheral blood T cells after single and multiple dose administration. Similar results were observed in peripheral blood B cells.

Also Read: FDA Grants Fast Track Review To Johnson & Johnson’s Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva

Sustained suppression of TCR-mediated T and B cell activation measured by CD69 was observed following single and multiple dose administration and ex vivo activation of whole blood.

Further development of MRT-6160 toward Phase 2 studies is ongoing in collaboration with Novartis AG (NYSE:NVS).

In October 2024, Monte Rosa Therapeutics announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160.

Novartis has agreed to pay Monte Rosa $150 million upfront. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory and sales milestones, beginning upon initiation of Phase 2 studies and tiered royalties on ex-U.S. net sales.

The company says cash, cash equivalents, restricted cash and marketable securities as of Dec. 31, 2024, of $377 million is expected to provide a cash runway into 2028.

GLUE Price Action: Monte Rosa Therapeutics stock is up 5.11% at $7.04 at publication Thursday.

Read Next:

• Nvidia Acquires Synthetic Data Firm Gretel To Train AI Models: Report

Photo: Shutterstock